{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05553834",
            "orgStudyIdInfo": {
                "id": "PRO00111111"
            },
            "organization": {
                "fullName": "Duke University",
                "class": "OTHER"
            },
            "briefTitle": "PCSK9 Inhibitor and PD-1 Inhibitor in Patients With Metastatic, Refractory To Prior Anti PD-1 Non-small Cell Lung",
            "officialTitle": "A Phase II Study of PCSK9 Inhibitor Alirocumab and PD-1 Inhibitor Cemiplimab in Patients With Metastatic, Refractory To Prior Anti PD-1 Non-small Cell Lung Cancer: TOP2201",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "inhibitor-and-pd-inhibitor-in-patients-with-metastatic-refractory-to-prior-anti-pd-non-small-cell-lung"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-05",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-05-16",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2027-01-01",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2029-01-01",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2022-09-02",
            "studyFirstSubmitQcDate": "2022-09-22",
            "studyFirstPostDateStruct": {
                "date": "2022-09-23",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-05-23",
            "lastUpdatePostDateStruct": {
                "date": "2024-05-24",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Duke University",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "Regeneron Pharmaceuticals",
                    "class": "INDUSTRY"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false,
            "isUsExport": false
        },
        "descriptionModule": {
            "briefSummary": "PCSK9 mediates immune checkpoint blockade resistance by downregulating tumor cell surface MHC class 1 molecules. This study will evaluate if combining the anti-PCSK9 antibody alirocumab with the anti-PD-1 antibody cemiplimab can generate anti-tumor activity and clinical responses in patients with metastatic lung cancer who have progressed on first line immune checkpoint blockade therapy."
        },
        "conditionsModule": {
            "conditions": [
                "Non-small Cell Lung Cancer (NSCLC)"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "interventionModelDescription": "Combination therapy involving anti-PCSK9 antibody alirocumab with the anti-PD-1 antibody cemiplimab.",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 60,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Alirocumab and Cemiplimab",
                    "type": "EXPERIMENTAL",
                    "description": "Combination of anti-PCSK9 antibody alirocumab with the anti-PD-1 antibody cemiplimab",
                    "interventionNames": [
                        "Combination Product: Alirocumab and Cemiplimab"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "COMBINATION_PRODUCT",
                    "name": "Alirocumab and Cemiplimab",
                    "description": "Combination of PCSK9 inhibitor Alirocumab 150mg SC q2weeks and PD-I inhibitor Cemiplimab 350mg IV q3 weeks",
                    "armGroupLabels": [
                        "Alirocumab and Cemiplimab"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Response rate associated with combination of alirocumab and cemiplimab",
                    "description": "Ascertain the response rate associated with alirocumab and cemiplimab, with 95% confidence intervals. Response rate is defined as the proportion of treated subjects with a complete or partial response per RECIST 1.1 criteria. All patients who receive at least one dose of alirocumab and cemiplimab will be considered for the primary outcome analysis",
                    "timeFrame": "Day 1 of treatment until the date of first documented progression or date of death, whichever comes first, assessed up to 110 weeks per RECIST 1.1"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Safety and tolerability of the combination regimen",
                    "description": "Toxicity analysis will be performed on a continual basis following CTC V 5.0 criteria",
                    "timeFrame": "Day 1 of treatment until 30 days post last dose"
                },
                {
                    "measure": "Progression Free Survival",
                    "description": "Progression Free Survival will be assessed utilizing RECIST 1.1 criteria",
                    "timeFrame": "Day 1 of treatment until the date of first documented progression or date of death, whichever comes first, assessed up to 110 weeks"
                },
                {
                    "measure": "Overall survival",
                    "description": "Patients will be followed till death or off study due to any other reason",
                    "timeFrame": "Day 1 of treatment until death or off study due to any other reason whichever comes first, assessed up to 110 weeks"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologically documented recurrent and/or metastatic non-small cell lung cancer\n* Progression after prior PD-1 directed therapy (as monotherapy or in combination with chemotherapy and/or anti-CTLA4, or anti-VEGF agents) - defined as investigator assessed progression from prior treatment\n* If molecularly altered NSCLC including EGFR, ALK, ROS1, MET exon 14, RET, BRAF, NTRK, progression on prior targeted therapy is required\n* Measurable disease by RECIST 1.1\n* ECOG Performance Status 0 or 1\n* Signed written informed consent\n* Minimum of 4 weeks from any other experimental anti-cancer therapies or prior PD-1 treatment\n* Meet all the laboratory criteria per protocol\n\nExclusion Criteria:\n\n* Prior treatment with PCSK9 inhibitors\n* Cardiac issues including MI, uncontrolled arrhythmia, symptomatic angina pectoris, active ischemia, or cardiac failure not controlled by medications.\n* Uncontrolled diabetes mellitus, defined as HbA1c \\> 10\n* Major surgery less than 4 weeks prior to study enrollment\n* Another malignant condition diagnosed within 3 years of study enrollment\n* Intolerance to prior PD-1/L1 treatment including discontinuation for severe or recurrent severe toxicity (including myocarditis or other myocardiotoxity, encephalitis, colitis, diarrhea, pancreatitis, hypo/hyperthyroidism, hypopituitarism, adrenal insufficiency, rash, autonomic neuropathy, myasthenia gravis, Guillain-Barre, myositis/polymyositis, hepatitis, Type 1 Diabetes, thrombocytopenia) or developed an immune checkpoint blockade related immune adverse event that was refractory to steroids and required additional systemic immunosuppressive medication.\n* Known history of HIV seropositivity or known acquired immunodeficiency syndrome (AIDS)\n* Additional exclusion criterion as per listed in the protocol",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Scott Antonia, MD",
                    "role": "CONTACT",
                    "phone": "919 681 9509",
                    "email": "scott.antonia@duke.edu"
                },
                {
                    "name": "Monika Anand, Ph.D",
                    "role": "CONTACT",
                    "phone": "9196818838",
                    "email": "monika.anand@duke.edu"
                }
            ],
            "locations": [
                {
                    "facility": "Moffitt Cancer Center",
                    "status": "RECRUITING",
                    "city": "Tampa",
                    "state": "Florida",
                    "zip": "33612",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Anahid Aminpour",
                            "role": "CONTACT",
                            "phone": "813-745-0287",
                            "email": "Anahid.Aminpour@moffitt.org"
                        }
                    ],
                    "geoPoint": {
                        "lat": 27.94752,
                        "lon": -82.45843
                    }
                },
                {
                    "facility": "Duke University",
                    "status": "RECRUITING",
                    "city": "Durham",
                    "state": "North Carolina",
                    "zip": "27705",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Scott Antonia, MD",
                            "role": "CONTACT"
                        },
                        {
                            "name": "Monika Anand, PhD",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 35.99403,
                        "lon": -78.89862
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000008175",
                    "term": "Lung Neoplasms"
                },
                {
                    "id": "D000002289",
                    "term": "Carcinoma, Non-Small-Cell Lung"
                }
            ],
            "ancestors": [
                {
                    "id": "D000012142",
                    "term": "Respiratory Tract Neoplasms"
                },
                {
                    "id": "D000013899",
                    "term": "Thoracic Neoplasms"
                },
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000008171",
                    "term": "Lung Diseases"
                },
                {
                    "id": "D000012140",
                    "term": "Respiratory Tract Diseases"
                },
                {
                    "id": "D000002283",
                    "term": "Carcinoma, Bronchogenic"
                },
                {
                    "id": "D000001984",
                    "term": "Bronchial Neoplasms"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M5546",
                    "name": "Carcinoma, Non-Small-Cell Lung",
                    "asFound": "Non-small Cell Lung Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M11172",
                    "name": "Lung Neoplasms",
                    "asFound": "Lung Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M5534",
                    "name": "Carcinoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M14979",
                    "name": "Respiratory Tract Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M16658",
                    "name": "Thoracic Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M11168",
                    "name": "Lung Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14977",
                    "name": "Respiratory Tract Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M5540",
                    "name": "Carcinoma, Bronchogenic",
                    "relevance": "LOW"
                },
                {
                    "id": "M5260",
                    "name": "Bronchial Neoplasms",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC08",
                    "name": "Respiratory Tract (Lung and Bronchial) Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "C000627974",
                    "term": "Cemiplimab"
                },
                {
                    "id": "C000571059",
                    "term": "Alirocumab"
                }
            ],
            "ancestors": [
                {
                    "id": "D000074322",
                    "term": "Antineoplastic Agents, Immunological"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000091362",
                    "term": "PCSK9 Inhibitors"
                },
                {
                    "id": "D000000924",
                    "term": "Anticholesteremic Agents"
                },
                {
                    "id": "D000000960",
                    "term": "Hypolipidemic Agents"
                },
                {
                    "id": "D000000963",
                    "term": "Antimetabolites"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000015842",
                    "term": "Serine Proteinase Inhibitors"
                },
                {
                    "id": "D000011480",
                    "term": "Protease Inhibitors"
                },
                {
                    "id": "D000004791",
                    "term": "Enzyme Inhibitors"
                },
                {
                    "id": "D000057847",
                    "term": "Lipid Regulating Agents"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M302522",
                    "name": "Cemiplimab",
                    "asFound": "RAD",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4225",
                    "name": "Antibodies",
                    "relevance": "LOW"
                },
                {
                    "id": "M2849",
                    "name": "PCSK9 Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M10184",
                    "name": "Immunoglobulins",
                    "relevance": "LOW"
                },
                {
                    "id": "M347350",
                    "name": "Alirocumab",
                    "asFound": "Share",
                    "relevance": "HIGH"
                },
                {
                    "id": "M1346",
                    "name": "Antineoplastic Agents, Immunological",
                    "relevance": "LOW"
                },
                {
                    "id": "M4243",
                    "name": "Anticholesteremic Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M4278",
                    "name": "Hypolipidemic Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M4281",
                    "name": "Antimetabolites",
                    "relevance": "LOW"
                },
                {
                    "id": "M14343",
                    "name": "Protease Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M18391",
                    "name": "Serine Proteinase Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M19609",
                    "name": "HIV Protease Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M7951",
                    "name": "Enzyme Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M28883",
                    "name": "Lipid Regulating Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "T18",
                    "name": "Serine",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "Lipd",
                    "name": "Lipid Regulating Agents"
                },
                {
                    "abbrev": "Infe",
                    "name": "Anti-Infective Agents"
                },
                {
                    "abbrev": "AA",
                    "name": "Amino Acids"
                }
            ]
        }
    },
    "hasResults": false
}